Payment overview · 2025
General Payments
$2,131.19
39 reported records · 18 companies
Healthcare provider profile · identity verified
Chintan B Shah, MD
Allopathic & Osteopathic Physicians|Family Medicine · FORT PIERCE, FL · NPI 1871782268
Verified facts
What the public records show
CMS Open Payments records show Chintan B Shah, MD received $2,131.19 in general payments during 2025 across 39 reported records.
PFIZER INC. accounted for 62.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 25 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Jardiance, Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LUMIGAN as an associated drug or biological on 25016 records involving 7645 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Lumigan by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 91 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 91 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 94 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 236 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 756 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| PFIZER INC. | Unresolved — no canonical attribution shown | $1,325.64 | 62.2% | 6 | 2025 |
| GE HEALTHCARE | Unresolved — no canonical attribution shown | $127.37 | 6.0% | 1 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $94.60 | 4.4% | 4 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $94.11 | 4.4% | 5 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $56.89 | 2.7% | 3 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $55.36 | 2.6% | 3 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $52.28 | 2.5% | 3 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $50.58 | 2.4% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $41.73 | 2.0% | 2 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $35.80 | 1.7% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $34.67 | 1.6% | 1 | 2025 |
| GENZYME CORPORATION | Unresolved — no canonical attribution shown | $30.68 | 1.4% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $24.62 | 1.2% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $24.36 | 1.1% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $23.59 | 1.1% | 1 | 2025 |
| Daiichi Sankyo Inc. | Unresolved — no canonical attribution shown | $21.15 | 1.0% | 1 | 2025 |
| Tactile Systems Technology Inc | Unresolved — no canonical attribution shown | $19.31 | 0.9% | 1 | 2025 |
| PhotoniCare Inc | Unresolved — no canonical attribution shown | $18.45 | 0.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $1,240.00 | 1 |
| Food and Beverage | $891.19 | 38 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $94.60 | 4 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $55.36 | 3 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $52.28 | 3 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $52.28 | 3 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $50.58 | 2 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $45.91 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $45.91 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $41.73 | 2 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $35.80 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $34.67 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $34.67 | 1 | 2025 |
Source payment records
|
|||||
| FABRAZYME Normalized: fabrazyme |
Biological | GENZYME CORPORATION | $30.68 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $24.62 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $24.36 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $23.59 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $21.68 | 1 | 2025 |
Source payment records
|
|||||
| INJECTAFER Normalized: injectafer |
Drug | Daiichi Sankyo Inc. | $21.15 | 1 | 2025 |
Source payment records
|
|||||
| Flexitouch Plus Normalized: flexitouch plus |
Device | Tactile Systems Technology Inc | $19.31 | 1 | 2025 |
Source payment records
|
|||||
| Nimbl Normalized: nimbl |
Device | Tactile Systems Technology Inc | $19.31 | 1 | 2025 |
Source payment records
|
|||||
| OtoSight Middle Ear Scope Normalized: otosight middle ear scope |
Device | PhotoniCare Inc | $18.45 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $17.67 | 1 | 2025 |
Source payment records
|
|||||
| JASCAYD Normalized: jascayd |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $17.14 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $15.98 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $12.05 | 2 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $12.05 | 2 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 756 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 19 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 91 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 236 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LUMIGAN open payments reported associated product |
CMS Open Payments — General Payments 25016 supporting records · 7645 recipient NPIs · example record 1201352548 |
Lumigan · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
31 | 12 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
33 | 14 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
91 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
91 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
94 | 12 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
236 | 39 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
41 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
756 | 157 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
24 | 24 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1291 | 359 |
| Amlodipine Besylate | Amlodipine Besylate | 1162 | 303 |
| Losartan Potassium | Losartan Potassium | 908 | 247 |
| Gabapentin | Gabapentin | 887 | 255 |
| Eliquis | Apixaban | 756 | 157 |
| Levothyroxine Sodium | Levothyroxine Sodium | 723 | 175 |
| Lisinopril | Lisinopril | 709 | 191 |
| Furosemide | Furosemide | 708 | 210 |
| Metformin Hcl | Metformin Hcl | 662 | 176 |
| Pantoprazole Sodium | Pantoprazole Sodium | 588 | 199 |
| Metoprolol Tartrate | Metoprolol Tartrate | 573 | 168 |
| Trazodone Hcl | Trazodone Hcl | 497 | 138 |
| Omeprazole | Omeprazole | 442 | 127 |
| Tamsulosin Hcl | Tamsulosin Hcl | 409 | 128 |
| Meloxicam | Meloxicam | 407 | 142 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 384 | 140 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 383 | 114 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 356 | 64 |
| Hydrochlorothiazide | Hydrochlorothiazide | 350 | 100 |
| Clopidogrel | Clopidogrel Bisulfate | 339 | 90 |
| Potassium Chloride | Potassium Chloride | 339 | 76 |
| Simvastatin | Simvastatin | 332 | 82 |
| Alprazolam | Alprazolam | 322 | 55 |
| Tramadol Hcl | Tramadol Hcl | 320 | 83 |
| Carvedilol | Carvedilol | 285 | 73 |
| Azithromycin | Azithromycin | 281 | 214 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 278 | 59 |
| Methylprednisolone | Methylprednisolone | 258 | 189 |
| Mirtazapine | Mirtazapine | 258 | 70 |
| Ozempic | Semaglutide | 236 | 39 |
| Allopurinol | Allopurinol | 223 | 59 |
| Metoprolol Succinate | Metoprolol Succinate | 223 | 76 |
| Sertraline Hcl | Sertraline Hcl | 210 | 57 |
| Buspirone Hcl | Buspirone Hcl | 202 | 68 |
| Hydralazine Hcl | Hydralazine Hcl | 194 | 48 |
| Fluticasone Propionate | Fluticasone Propionate | 192 | 83 |
| Donepezil Hcl | Donepezil Hcl | 186 | 41 |
| Finasteride | Finasteride | 184 | 55 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 183 | 135 |
| Glipizide | Glipizide | 179 | 57 |
| Atenolol | Atenolol | 173 | 48 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 169 | 79 |
| Prednisone | Prednisone | 167 | 108 |
| Ondansetron Hcl | Ondansetron Hcl | 157 | 62 |
| Escitalopram Oxalate | Escitalopram Oxalate | 155 | 47 |
| Clonazepam | Clonazepam | 154 | 23 |
| Zolpidem Tartrate | Zolpidem Tartrate | 151 | 32 |
| Levetiracetam | Levetiracetam | 147 | 38 |
| Citalopram Hbr | Citalopram Hydrobromide | 145 | 31 |
| Nifedipine Er | Nifedipine | 144 | 44 |
| Duloxetine Hcl | Duloxetine Hcl | 141 | 35 |
| Tizanidine Hcl | Tizanidine Hcl | 137 | 56 |
| Diclofenac Sodium | Diclofenac Sodium | 136 | 53 |
| Montelukast Sodium | Montelukast Sodium | 136 | 35 |
| Diazepam | Diazepam | 134 | 32 |
| Doxycycline Hyclate | Doxycycline Hyclate | 134 | 90 |
| Glipizide Er | Glipizide | 127 | 36 |
| Pravastatin Sodium | Pravastatin Sodium | 126 | 45 |
| Fenofibrate | Fenofibrate | 125 | 36 |
| Famotidine | Famotidine | 123 | 44 |
| Methocarbamol | Methocarbamol | 123 | 66 |
| Clonidine Hcl | Clonidine Hcl | 115 | 44 |
| Ibuprofen | Ibuprofen | 113 | 47 |
| Memantine Hcl | Memantine Hcl | 111 | 24 |
| Quetiapine Fumarate | Quetiapine Fumarate | 109 | 26 |
| Cefdinir | Cefdinir | 107 | 83 |
| Cephalexin | Cephalexin | 106 | 72 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 101 | 75 |
| Baclofen | Baclofen | 100 | 27 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 97 | 27 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 97 | 34 |
| Alendronate Sodium | Alendronate Sodium | 96 | 21 |
| Oxycodone Hcl | Oxycodone Hcl | 96 | 25 |
| Cefuroxime | Cefuroxime Axetil | 95 | 78 |
| Nystatin | Nystatin | 94 | 41 |
| Trulicity | Dulaglutide | 94 | 12 |
| Jardiance | Empagliflozin | 91 | suppressed |
| Spironolactone | Spironolactone | 90 | 22 |
| Enalapril Maleate | Enalapril Maleate | 88 | 19 |
| Amoxicillin | Amoxicillin | 87 | 59 |
| Divalproex Sodium | Divalproex Sodium | 85 | 17 |
| Ezetimibe | Ezetimibe | 85 | 27 |
| Lovastatin | Lovastatin | 84 | 23 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 84 | 45 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 83 | 66 |
| Meclizine Hcl | Meclizine Hcl | 82 | 40 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 80 | 23 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 79 | 17 |
| Januvia | Sitagliptin Phosphate | 77 | 16 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 76 | 18 |
| Doxazosin Mesylate | Doxazosin Mesylate | 75 | 13 |
| Amiodarone Hcl | Amiodarone Hcl | 71 | 26 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 69 | 52 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 68 | 19 |
| Temazepam | Temazepam | 67 | 13 |
| Testosterone Cypionate | Testosterone Cypionate | 66 | 12 |
| Xarelto | Rivaroxaban | 63 | 15 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 61 | 11 |
| Fluoxetine Hcl | Fluoxetine Hcl | 61 | 22 |
| Fluconazole | Fluconazole | 60 | 37 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 60 | 17 |
| Midodrine Hcl | Midodrine Hcl | 60 | 23 |
| Ropinirole Hcl | Ropinirole Hcl | 60 | 14 |
| Bumetanide | Bumetanide | 59 | 14 |
| Lorazepam | Lorazepam | 59 | 21 |
| Pregabalin | Pregabalin | 58 | 16 |
| Amitriptyline Hcl | Amitriptyline Hcl | 57 | 16 |
| Latanoprost | Latanoprost | 57 | 16 |
| Oxybutynin Chloride | Oxybutynin Chloride | 57 | 17 |
| Sucralfate | Sucralfate | 57 | 34 |
| Pioglitazone Hcl | Pioglitazone Hcl | 56 | 11 |
| Ondansetron Odt | Ondansetron | 55 | 21 |
| Lamotrigine | Lamotrigine | 53 | 12 |
| Sumatriptan Succinate | Sumatriptan Succinate | 51 | 12 |
| Valsartan | Valsartan | 51 | 15 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 48 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 48 | 17 |
| Lactulose | Lactulose | 48 | 19 |
| Breo Ellipta | Fluticasone/Vilanterol | 46 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 46 | 11 |
| Labetalol Hcl | Labetalol Hcl | 45 | suppressed |
| Topiramate | Topiramate | 45 | 15 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 44 | 14 |
| Celecoxib | Celecoxib | 44 | 11 |
| Fenofibrate | Fenofibrate Nanocrystallized | 44 | 14 |
| Tresiba Flextouch U-100 | Insulin Degludec | 44 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 44 | 11 |
| Hydrocortisone | Hydrocortisone | 43 | 28 |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 41 | 24 |
| Rybelsus | Semaglutide | 41 | suppressed |
| Levofloxacin | Levofloxacin | 40 | 30 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 38 | suppressed |
| Scopolamine | Scopolamine | 37 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 37 | 12 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 36 | suppressed |
| Movantik | Naloxegol Oxalate | 35 | suppressed |
| Digoxin | Digoxin | 34 | 12 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 34 | 12 |
| Minocycline Hcl | Minocycline Hcl | 34 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 34 | suppressed |
| Tradjenta | Linagliptin | 34 | suppressed |
| Acyclovir | Acyclovir | 33 | 12 |
| Fenofibrate | Fenofibrate,micronized | 33 | suppressed |
| Gemfibrozil | Gemfibrozil | 33 | suppressed |
| Naproxen | Naproxen | 33 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 33 | 14 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 32 | 14 |
| Bupropion Xl | Bupropion Hcl | 31 | 12 |
| Glimepiride | Glimepiride | 31 | 12 |
| Metoclopramide Hcl | Metoclopramide Hcl | 31 | 11 |
| Synthroid | Levothyroxine Sodium | 31 | 12 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 30 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 30 | suppressed |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 30 | 13 |
| Ketoconazole | Ketoconazole | 30 | 11 |
| Sodium Chloride | 0.9 % Sodium Chloride | 30 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 30 | 18 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 29 | 12 |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 29 | suppressed |
| Risperidone | Risperidone | 29 | suppressed |
| Entresto | Sacubitril/Valsartan | 28 | suppressed |
| Mupirocin | Mupirocin | 28 | 18 |
| Myrbetriq | Mirabegron | 28 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 28 | 13 |
| Estradiol | Estradiol | 27 | 11 |
| Nitroglycerin | Nitroglycerin | 27 | 16 |
| Clotrimazole | Clotrimazole | 26 | 14 |
| Folic Acid | Folic Acid | 26 | suppressed |
| Novolin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 26 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 25 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 25 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 24 | suppressed |
| Brilinta | Ticagrelor | 24 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 24 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 24 | 24 |
| Venlafaxine Hcl | Venlafaxine Hcl | 24 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 24 | suppressed |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 23 | suppressed |
| Chlorthalidone | Chlorthalidone | 23 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 23 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 23 | 17 |
| Novolin 70-30 Flexpen | Insulin Nph Hum/Reg Insulin Hm | 23 | suppressed |
| Permethrin | Permethrin | 23 | 13 |
| Ramipril | Ramipril | 23 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 23 | suppressed |
| Anastrozole | Anastrozole | 22 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 22 | 12 |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 22 | suppressed |
| Carbamazepine | Carbamazepine | 21 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 21 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 21 | suppressed |
| Lidocaine | Lidocaine | 21 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 21 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 20 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 20 | 12 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 20 | suppressed |
| Novolog Flexpen | Insulin Aspart | 20 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 20 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 20 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 19 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 19 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 19 | suppressed |
| Methotrexate | Methotrexate Sodium | 19 | suppressed |
| Metronidazole | Metronidazole | 19 | 18 |
| Promethazine Hcl | Promethazine Hcl | 19 | suppressed |
| Zonisamide | Zonisamide | 19 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 18 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 18 | suppressed |
| Neomycin-Polymyxin-Hc | Neomycin/Polymyxin B/Hydrocort | 18 | 16 |
| Primidone | Primidone | 18 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 17 | suppressed |
| Dulera | Mometasone/Formoterol | 17 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 17 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 17 | suppressed |
| Irbesartan | Irbesartan | 17 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 17 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 17 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 16 | 16 |
| Dicyclomine Hcl | Dicyclomine Hcl | 16 | suppressed |
| Imipramine Hcl | Imipramine Hcl | 16 | suppressed |
| Linzess | Linaclotide | 16 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 16 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 16 | suppressed |
| Colchicine | Colchicine | 15 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 15 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 15 | suppressed |
| Lumigan | Bimatoprost | 15 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 15 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 14 | suppressed |
| Descovy | Emtricitabine/Tenofov Alafenam | 14 | suppressed |
| Elinest | Norgestrel-Ethinyl Estradiol | 14 | suppressed |
| Etravirine | Etravirine | 14 | suppressed |
| Isentress | Raltegravir Potassium | 14 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 14 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 14 | suppressed |
| Nabumetone | Nabumetone | 14 | suppressed |
| Neomycin-Polymyxin-Hydrocort | Neomycin/Polymyxin B/Hydrocort | 14 | suppressed |
| Prezcobix | Darunavir/Cobicistat | 14 | suppressed |
| Pyridostigmine Bromide | Pyridostigmine Bromide | 14 | suppressed |
| Tivicay | Dolutegravir Sodium | 14 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 13 | suppressed |
| Aptiom | Eslicarbazepine Acetate | 13 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 13 | 11 |
| Constulose | Lactulose | 13 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 13 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 13 | 11 |
| Metolazone | Metolazone | 13 | suppressed |
| Nateglinide | Nateglinide | 13 | suppressed |
| Nyamyc | Nystatin | 13 | suppressed |
| Nystatin-Triamcinolone | Nystatin/Triamcinolone Acet | 13 | suppressed |
| Prochlorperazine Maleate | Prochlorperazine Maleate | 13 | suppressed |
| Ursodiol | Ursodiol | 13 | suppressed |
| Zenpep | Lipase/Protease/Amylase | 13 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 12 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 12 | suppressed |
| Clonidine | Clonidine | 12 | suppressed |
| Gemtesa | Vibegron | 12 | suppressed |
| Keppra | Levetiracetam | 12 | suppressed |
| Loperamide | Loperamide Hcl | 12 | 12 |
| Neomycin-Polymyxin-Dexameth | Neomycin/Polymyxin B/Dexametha | 12 | suppressed |
| Ranolazine Er | Ranolazine | 12 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 12 | suppressed |
| Tybost | Cobicistat | 12 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 11 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 11 | suppressed |
| Cefazolin Sodium | Cefazolin Sodium | 11 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 11 | suppressed |
| Diltiazem 24hr Er (La) | Diltiazem Hcl | 11 | suppressed |
| Gentamicin Sulfate | Gentamicin Sulfate | 11 | suppressed |
| Humulin 70/30 Kwikpen | Insulin Nph Hum/Reg Insulin Hm | 11 | suppressed |
| Hydroxyurea | Hydroxyurea | 11 | suppressed |
| Indomethacin | Indomethacin | 11 | suppressed |
| Levemir Flexpen | Insulin Detemir | 11 | suppressed |
| Nitroglycerin Patch | Nitroglycerin | 11 | suppressed |
| Novolin R | Insulin Regular, Human | 11 | suppressed |
| Olanzapine | Olanzapine | 11 | suppressed |
| Prasugrel Hcl | Prasugrel Hcl | 11 | suppressed |
| Telmisartan | Telmisartan | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $2,131.19 · 39 records | PFIZER INC. | ABRYSVO, AIRSUPRA, AUSTEDO XR, BREZTRI, Dexcom G6 Transmitter, ELIQUIS, FABRAZYME, FARXIGA, FREESTYLE LIBRE 3, Flexitouch Plus, INJECTAFER, JARDIANCE, JASCAYD, Korlym, Leqembi, NURTEC ODT, Nimbl, OTEZLA, OtoSight Middle Ear Scope, Ozempic, PREVNAR 20, QULIPTA, REPATHA, UBRELVY, XIFAXAN | 13 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error